·Î¶¯ÂöÖØ½¨,pulmonary artery reconstructionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ͳ¼Æ²ÎÊýµØÍ¼,Statistical parametric mappingÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÍÑÑõ°ûÜÕ/ÖÎÁÆÓ¦ÓÃ,deoxycytidine/therapeutic useÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« µ°°×ÀÒ°±ËἤøÒÖÖÆ¼Á,Protein tyrosine kinase inhibitorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¼ÁÁ¿Ç¿¶È,Dose intensityÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÃâÒßÒÖÖÆÒò×Ó,Immunosuppressive factorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¿ÉÈÜÐÔ°×ϸ°û½éËØ-6ÊÜÌå,Soluble Interleukin-6 ReceptorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÍíÆÚ·ÎÏÙ°©,Advanced lung adenocarcinomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« 4.1µ°°×,Protein 4.1Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÌøÔ¾×ªÒÆ,Skip metastasisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ·Î¸ôÀë¹à×¢,isolated lung perfusionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« µòÍöÒÖÖÆÒò×Ó,apoptosis inhibitorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¶à·Ö±æÂÊÖ±·½Í¼,multi-resolution histogramÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« G1ÆÚ×èÖÍ,G 1 arrestÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ö×Áö¸Éϸ°û²â¶¨,Tumor stem cell assayÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ×éÖ¯·Ö»¯,Tissue differentiationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Áܰ͹ÜÇÖ·¸,Lymphatic vessel invasionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ·Ê´óÐԹǹؽڲ¡,hypertrophic osteoarthropathyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« È¥¼×°ßòúËáÄÆ,Sodium DemethylcantharidateÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ô¤·ÀÐÔÄÔÕÕÉä,prophylactic cranial irradiationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ·ÎѪ¹Ü,pulmonary vesselÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« NCI-H460ϸ°û,NCI-H460 cellÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« 125I·ÅÉäÐÔÁ£×Ó,125I radioactive seedÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ·ÇСϸ°û·Î/´úл,non-small cell lung/metabolismÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÏßÁ£ÌåÈںϵ°°×2,mitofusin 2Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« Æø¹ÜÖ×Áö/Õï¶Ï,Tracheal Neoplasms/diagnosisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Á×Ö¬õ£¼¡´¼3¼¤Ã¸Í¨µÀ,PI3 K pathwayÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ðä×´Çгý,Sleeve resectionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« 99Tcm±ê¼Ç,99Tcm labellingÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ò©ÎïÄÍÒ©,drug resistanceÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÈË·ÎÏÙ°©A549ϸ°û,human lung adenocarcinoma A549 cellsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« TÁܰÍÁöÇÖÏ®×ªÒÆÓÕµ¼Òò×Ó1,Tiam 1Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« ·Î×ªÒÆÁö/·ÅÉäÖÎÁÆ,lung metastases/radiotherapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ó¸ËÖ×¢ÉäÒº,secretio bufonis injectionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÇàÄêÄÐÐÔ,young menÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ΢ÈéÍ·½á¹¹,micropapillary patternÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¸ßƵµçµ¶Êõ,high frequency electrocauteryÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« °©ÅÔ×éÖ¯,Paracancerous tissueÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« È˷ΰ©Ï¸°ûÖê,human lung cancer cell lineÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ·ÎÁÛ°©,lung squamous carcinomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ö×ÁöÑù²¡±ä,tumor-like lesionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ·Î¶¯Âö³ÉÐÎ,Pulmonary arterioplastyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÈýάÁ¢ÌåÅàÑø,three-dimensional cultureÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÑÒÊæ,YanshuÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Æø¹ÜÇгý,tracheal resectionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÄÍÒ©Ïà¹Ø»ùÒò,Drug resistance-related genesÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¹ÂÁ¢ÐÔ·ÎÄÚ½á½Ú,Solitary pulmonary noduleÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ·Î°©/Õï¶Ï,lung cancer/diagnosisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ·úÍÑÑõÆÏÌÑÌÇF18/Õï¶ÏÓ¦ÓÃ,Fluorodeoxyglucose F18/diagnostic useÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ·Î¶ñÐÔÖ×Áö,Lung neoplasmÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« È˶ËÁ£Ã¸Äæ×ªÂ¼Ã¸»ùÒò,human telomerase reverse transcriptaseÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ºÚÉ«ËØÁö¿¹Ô­»ùÒò,melanoma antigen geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¶þÏßÖÎÁÆ,second-line therapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÏÙÁÛ°©,Adenosquamous carcinomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« É䯵ÏûÈÚÖÎÁÆ,Radiofrequency ablationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Pokemonµ°°×,Pokemon proteinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Çå½ðµÃÉúƬ,Qing jin de sheng tabletsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Âö¹ÜÁö˨,intravascular cancer embolusÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« H460ϸ°û,H460 cellÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« öèÓãÈí¹ÇËØ,shark cartilageÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ±íƤÉú³¤Òò×Ó/Þ׿¹¼ÁºÍÒÖÖÆ¼Á,Epidermal Growth Factor/antagonists and inhibitorsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¼××´ÏÙת¼Òò×Ó1,Thyroid transcription factor 1Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÄÔ×ªÒÆ°©,cerebral metastatic carcinomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ö×Áö¿ÉÈÜÐÔ¿¹Ô­,tumor soluble antigenÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ·Å»¯ÁÆÍ¬²½ÖÎÁÆ,Chemo-radiotherapy concomitant therapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¶ñÐÔÉñ¾­ÇÊÁö,Malignant neurilemomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ²ÎÂó×¢Éä¼Á,Shenmai injectionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Àà°©×ÛºÏÕ÷,Carcinoid syndromeÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ´«Í³Í¿Æ¬,conventional smearÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¼Æ»®°ÐÌå»ý,Planning target volumeÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¢óÆÚ·ÇСϸ°û·Î°©,stage ¢ó non-small cell lung cancerÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ºó³Ì¼ÓËÙ³¬·Ö¸î·ÅÁÆ,Late course accelerated hyperfractionation radiotherapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« KMG΢Çò,KMG microballoonsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÉÏÆ¤Ö×Áö,Epithelial neoplasmsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÍÑÑõ°ûÜÕ/ͶҩºÍ¼ÁÁ¿,deoxycytidine/administration & dosageÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¿ËÁöÍè,Keliu PillÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ·ÇСϸ°û·Î/ÖÎÁÆ,non-small cell lung/therapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ö×Áö½þÈó×ªÒÆ,Mta1 geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« LunxmRNA,Lunx mRNAÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ·ÎÅÝϸ°û°©,bronchioloalveolar carcinomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ·Î°©ÈâÁö,Pulmonary CarcinosarcomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« µçÊÓ×ݸô¾µ¼ì²é,Video mediastinoscopyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ·Î°©Ï¸°ûPG,PG cellÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« caspase9,caspase 9Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« ·ÎÏÙ°©Ï¸°ûÖê,lung adenocarcinoma cellÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ·ÎÈâÁö,Pulmonary sarcomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« A-549ϸ°û,A-549 cellsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¹®¹Ì»¯ÁÆ,consolidation chemotherapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¾Ö²¿ÍíÆÚ·ÇСϸ°û·Î°©,local advanced non-small cell lung cancerÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ì춬°±ËáÄÚëÄøÀà,Aspartic endopeptidasesÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ·Î°©×ªÒÆ,Lung cancer metastasisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« »ìÔÓÒòËØ,confounding factorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ³¤´ºÈð±õ/ÖÎÁÆÓ¦ÓÃ,Vinorelbine/therapeutic useÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¹Èë׸ÊëÄÁò×ªÒÆÃ¸M1,glutathione S-transferase M1Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« ErbB2µ°°×,ErbB2 proteinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« YB-1µ°°×,YB-1 proteinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« VEGF-Cµ°°×,VEGF-C proteinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¿¹Ö×ÁöÒßÃç,anti-cancer vaccineÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ò°ÉúÐÍp53,wild type p53Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÖÂÁöÐÔÊÔÑé,Carcinogenicity testsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«